Emily Chan

11.2k total citations · 3 hit papers
90 papers, 4.8k citations indexed

About

Emily Chan is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Emily Chan has authored 90 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 36 papers in Surgery and 23 papers in Molecular Biology. Recurrent topics in Emily Chan's work include Colorectal Cancer Treatments and Studies (17 papers), Pancreatic and Hepatic Oncology Research (14 papers) and Colorectal and Anal Carcinomas (8 papers). Emily Chan is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Pancreatic and Hepatic Oncology Research (14 papers) and Colorectal and Anal Carcinomas (8 papers). Emily Chan collaborates with scholars based in United States, Canada and United Kingdom. Emily Chan's co-authors include Michael A. Morse, Ahmed Nasr, Carolyn Wayne, Christine H. Chung, Barbara A. Murphy, David Mauro, Qinwei Zhou, Shama M. Satinover, Diane R. Gold and Beloo Mirakhur and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Emily Chan

87 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

2008 1.1k citations Emily Chan, Michael A. Morse et al. profile →
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

2015 513 citations Scott Kopetz, Jayesh Desai et al. Journal of Clinical Oncology profile →
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

2016 511 citations Padmanee Sharma, Margaret K. Callahan et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emily Chan United States	29	2.1k	1.7k	1.4k	802	746	90	4.8k
Satoshi Fujii Japan	44	2.4k 1.2×	2.3k 1.4×	1.2k 0.9×	1.4k 1.7×	674 0.9×	271	6.7k
Sufi M. Thomas United States	43	2.2k 1.0×	2.7k 1.6×	435 0.3×	1.0k 1.3×	486 0.7×	106	5.2k
Jerry Ware United States	50	1.0k 0.5×	2.0k 1.1×	1.1k 0.8×	1.1k 1.3×	1.4k 1.9×	148	8.4k
Cornelis F.M. Sier Netherlands	43	2.1k 1.0×	1.9k 1.1×	690 0.5×	678 0.8×	763 1.0×	130	5.4k
Maria Flavia Di Renzo Italy	40	1.9k 0.9×	4.0k 2.4×	1.3k 1.0×	959 1.2×	559 0.7×	106	7.4k
Toshiyuki Ishiwata Japan	47	2.5k 1.2×	3.6k 2.1×	692 0.5×	586 0.7×	692 0.9×	215	6.4k
Yasushi Ichikawa Japan	43	2.4k 1.2×	1.4k 0.8×	1.3k 1.0×	1.0k 1.3×	281 0.4×	247	5.0k
Reinhard Horvat Austria	40	1.4k 0.7×	1.8k 1.1×	631 0.5×	474 0.6×	544 0.7×	106	4.2k
Marc Mareel Belgium	27	1.4k 0.7×	1.7k 1.0×	502 0.4×	574 0.7×	460 0.6×	47	3.9k
Léon C.L.T. van Kempen Netherlands	39	1.6k 0.8×	1.7k 1.0×	704 0.5×	631 0.8×	661 0.9×	132	4.2k

Countries citing papers authored by Emily Chan

Since Specialization

Citations

This map shows the geographic impact of Emily Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Chan more than expected).

Fields of papers citing papers by Emily Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Chan. The network helps show where Emily Chan may publish in the future.

Co-authorship network of co-authors of Emily Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Chan. A scholar is included among the top collaborators of Emily Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Chan. Emily Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chan, Emily, et al.. (2025). Live surgery increases operative time but not complication rate in patients undergoing arthroscopic anatomic glenoid reconstruction. Journal of ISAKOS Joint Disorders & Orthopaedic Sports Medicine. 12. 100868–100868.

Li, Ye, Emily Chan, Esther Puyol‐Antón, et al.. (2023). Hemodynamic Determinants of Elevated Blood Pressure and Hypertension in the Middle to Older-Age UK Population: A UK Biobank Imaging Study. Hypertension. 80(11). 2473–2484. 1 indexed citations

Hong, David S., Patricia LoRusso, Omid Hamid, et al.. (2018). Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 25(8). 2403–2413. 42 indexed citations

Chan, Emily, Stephen R. Gannon, Chevis N. Shannon, et al.. (2017). The impact of curve severity on obstetric complications and regional anesthesia utilization in pregnant patients with adolescent idiopathic scoliosis: a preliminary analysis. Neurosurgical FOCUS. 43(4). E4–E4. 11 indexed citations

Jin, Lingyan, Emily Chan, Ehud Segal, et al.. (2017). Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. Cancer Research. 77(20). 5564–5575. 105 indexed citations

Sullivan, Katrina, Michelle Li, Sarah McCann Haworth, et al.. (2017). Optimal age for elective surgery of asymptomatic congenital pulmonary airway malformation: a meta-analysis. Pediatric Surgery International. 33(6). 665–675. 12 indexed citations

Tolcher, Anthony W., Jordan Berlin, Jan Cosaert, et al.. (2017). A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 79(4). 673–680. 80 indexed citations

Wayne, Carolyn, et al.. (2016). Formula-feeding and hypertrophic pyloric stenosis: is there an association? A case–control study. Journal of Pediatric Surgery. 51(5). 779–782. 11 indexed citations

Sharma, Padmanee, Margaret K. Callahan, Petri Bono, et al.. (2016). Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet Oncology. 17(11). 1590–1598. 511 indexed citations breakdown →

10.

Kopetz, Scott, Jayesh Desai, Emily Chan, et al.. (2015). Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer. Journal of Clinical Oncology. 33(34). 4032–4038. 513 indexed citations breakdown →

11.

Chan, Emily, Eunice L. Kwak, Jimmy Hwang, et al.. (2015). Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease. Cancer Chemotherapy and Pharmacology. 75(4). 701–709. 17 indexed citations

12.

Sullivan, Katrina, et al.. (2015). Feeding Post-Pyloromyotomy: A Meta-analysis. PEDIATRICS. 137(1). 19 indexed citations

13.

Wu, Huali, Jeffrey R. Infante, Vicki L. Keedy, et al.. (2015). Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. International Journal of Nanomedicine. 10. 1201–1201. 14 indexed citations

14.

Lee, Adam M, Qian Shi, Steven R. Alberts, et al.. (2015). Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients. Pharmacogenetics and Genomics. 26(3). 133–137. 27 indexed citations

15.

Peeters, Marc, Kelly S. Oliner, Timothy Price, et al.. (2014). KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated Analysis. Annals of Oncology. 25. ii5–ii5. 2 indexed citations

16.

Goff, Laura W., Nilay Thakkar, Liping Du, et al.. (2014). Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers. PLoS ONE. 9(9). e107424–e107424. 80 indexed citations

17.

Rosen, Lee S., Igor Puzanov, Gregory Friberg, et al.. (2012). Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(12). 3414–3427. 30 indexed citations

18.

Holland, Sacha J., Mark Powell, Christian Franci, et al.. (2005). Multiple Roles for the Receptor Tyrosine Kinase Axl in Tumor Formation. Cancer Research. 65(20). 9294–9303. 161 indexed citations

19.

Carvalho, Marcelo A., et al.. (2002). Mutations in the BRCT Domain Confer Temperature Sensitivity to BRCA1 in Transcription Activation. Cancer Biology & Therapy. 1(5). 502–508. 13 indexed citations

20.

Christensen, James G., Randall Schreck, Emily Chan, et al.. (2001). High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.. PubMed. 7(12). 4230–8. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact